James L. Freddo, M.D.

Dr. Freddo is a veteran biotech executive and consultant with more than 25 years of experience leading clinical development teams, designing oncology drug development and regulatory strategies, and conducting clinical trials. He has held senior roles in large and small pharmaceutical companies and has co-founded multiple biotechnology startups.  Achievements during his career include the successful development and approval of multiple anti-cancer therapeutics.

After acting as a Consultant Chief Medical Officer at Ignyta, he joined the Board of Directors where he served until its acquisition by Roche in 2018. James was formerly the Chief Medical Officer and Senior Vice President, Drug Development and a member of the Board of Directors at Anadys Pharmaceuticals, which was also acquired by Roche in 2011. Prior to joining Anadys Pharmaceuticals, he served at Pfizer, holding the positions of Vice President, Clinical Site Head, and Development Site Head and, prior to that, Executive Director and leader of Oncology Clinical Development. While at Pfizer, Dr. Freddo built and led the team responsible for the registration of Sutent® (sunitinib malate), a drug approved by the U.S. Food and Drug Administration in January 2006 for treating advanced kidney cancer and gastrointestinal stromal tumors. Dr. Freddo also designed the early clinical development strategy for Axitinib which was approved by the FDA for the treatment of renal cell carcinoma in 2012. Prior to Pfizer, he held a variety of senior management positions at Wyeth-Ayerst Research, in the oncology, infectious diseases, and transplantation/immunology therapeutic areas. He has also served as a member of the Board of Directors for InfuSystems, Inc., a public healthcare products and services company.

Dr. Freddo received an M.D. degree from the University of North Carolina, Chapel Hill; completed his residency training at University of California, San Diego; and returned to Chapel Hill for his fellowship training in gynecologic oncology. He practiced in academic and private practice settings prior to joining the pharmaceutical industry.

James is a clinical advisor to Boundless Bio.